Alkixa

Quick links to important sections

Alkixa

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alkixa

Property Description
Active Ingredient Aldioxa (Dihydroxyaluminum Allantoinate)
Form Tablets, Granules (Oral); Creams, Lotions, Ointments (Topical)
Pharmacological Class Gastrointestinal Agent, Gastric Mucosal Protectant, Astringent
Common Use Protection and healing of irritated or damaged mucosal and epithelial tissues.
Origin Synthetic Coordination Compound

What is Alkixa and its Classification as a Mucosal Protectant?

Alkixa is a pharmaceutical preparation whose sole active component is the substance Aldioxa, known chemically as Dihydroxyaluminum Allantoinate. It is classified as a Gastrointestinal Agent, specifically a Gastric Mucosal Protectant, reflecting its primary internal function. Unlike simple Aluminum Hydroxide, which provides basic acid neutralization, Aldioxa is a synthetic coordination compound created by chemically combining Allantoin with Aluminum Hydroxide. This distinctive complex is recognized for its anti-ulcerative and skin-protecting properties, positioning it within a class that supports tissue integrity.

Composition and Available Delivery Types

The preparation is fundamentally a single-active-ingredient product featuring Aldioxa, which dictates the variety of its commercial dosage forms and intended application routes. For internal systemic use, it is manufactured as Tablets or Granules, intended for Oral administration targeting the digestive tract. The compound is also associated with improving gastric emptying. Conversely, the same active ingredient is utilized in various Creams and Ointments for Topical application, where its soothing and astringent actions are leveraged on the external epithelial layers of the skin.

The General Purpose of Aldioxa: Tissue Healing and Protection

The general therapeutic purpose of Alkixa is to support the restoration of compromised tissues by providing both physical defense and regenerative stimulus. Aldioxa offers Targeted Tissue Protection by creating a localized, stable barrier over the irritated site, while concurrently promoting Cellular Regeneration through the activity of its Allantoin moiety. This combined function ensures the affected area is shielded from further irritants, such as stomach acid or friction, while supporting the body’s intrinsic healing mechanisms.

Regulatory References

  1. NIH Research on Gastric Function Improvement

What side effects are possible with Alkixa?

Possible Side Effects and Safety Information

The safety profile for Alkixa (Alectinib) is defined by regulatory agencies based on categorized adverse reactions and specific warnings. Adverse reactions are classified according to their frequency in clinical data, ranging from Very Common to Uncommon. Monitoring protocols are mandated due to the potential for clinically significant effects.

Frequency-Classified Adverse Reactions

Classification Examples of Adverse Reactions (SOC)
Very Common (ge 1/10) Fatigue, Constipation, Peripheral Edema, Myalgia, Anemia
Common (ge 1/100 to < 1/10) Bradycardia, Vision Impairment, Rash, Renal Impairment
Uncommon (ge 1/1,000 to < 1/100) Interstitial Lung Disease (ILD)/Pneumonitis

Serious Adverse Reactions and Affected Systems

The official labeling documents several serious adverse reactions associated with the use of Alkixa. These include significant effects on key organ systems. Hepatotoxicity (severe liver injury) is documented, often detected by increased transaminases and bilirubin, and requires monitoring. Musculoskeletal and Connective Tissue Disorders may manifest as severe myalgia, potentially progressing to Rhabdomyolysis. Additionally, Cardiac Disorders are noted, including the risk of Severe Bradycardia (slow heart rate), and Respiratory, Thoracic, and Mediastinal Disorders include the risk of ILD/Pneumonitis.

Specific safety considerations exist for special populations. Older patients (aged 65 years and over) have reported higher rates of certain common effects such as fatigue and edema. For patients with hepatic impairment, caution is advised, as increased drug exposure is documented, necessitating careful monitoring based on the regulatory safety framework.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents do not define a specific clinical symptom set for an acute overdose of Alkixa (Alectinib). Instead, the risk is defined by the potential for known severe, life-threatening adverse reactions to be exacerbated at high exposure levels.

Documented Overdose Risks and Manifestations

Classification Official Regulatory Statement
Toxicity Risk Potential to intensify severe adverse reactions, including life-threatening bradycardia (slow heart rate) and hepatotoxicity (liver injury).
Immediate Action Management consists of general supportive measures; no specific antidote is available.
Procedural Constraint Hemodialysis is unlikely to be effective due to the substance’s high protein-binding capacity in the plasma.

When Urgent Medical Attention is Required

Urgent medical help must be sought immediately if a suspected overdose has occurred, or if severe symptoms are observed. This includes clinical signs such as collapse, a seizure, trouble breathing, or if the individual cannot be awakened. Furthermore, the development of symptomatic or life-threatening bradycardia requires immediate medical evaluation, as regulatory guidelines mandate close patient monitoring of the patient’s clinical status and potential discontinuation of the substance.

Therapeutic Uses of Alkixa

Quick Facts: Alkixa's Approved Therapeutic Domains

  • Targeted Therapy: Helps manage ALK-positive non-small cell lung cancer (NSCLC).
  • Adjuvant Treatment: Used following tumor resection in certain adult patients with ALK-positive NSCLC (tumors ≥ 4 cm or node positive).
  • Metastatic Disease: Indicated for the management of adult patients with ALK-positive NSCLC that has spread to other parts of the body.

What Alkixa Treats: Main Uses and Benefits

Alkixa is a prescription medication utilized in oncology for the management of non-small cell lung cancer (NSCLC) that is positive for an anaplastic lymphoma kinase (ALK) gene rearrangement. Its indications focus on two distinct therapeutic domains in adults.

First, Alkixa is used as an adjuvant treatment following the complete surgical removal of the tumor in patients with ALK-positive NSCLC classified as Stage IB (tumors ≥ 4 cm), Stage II, or Stage IIIA. This use is intended to manage the risk of cancer recurrence following surgery.

Second, Alkixa is also indicated for the management of metastatic ALK-positive NSCLC. This involves managing the disease in patients where the cancer has progressed to other areas of the body, offering a therapeutic option for patients with this specific molecular characteristic.

Eligibility and Restrictions for Use

Alkixa (commonly known by the active ingredient apixaban) is a prescription anticoagulant used to prevent and treat blood clots. It is generally suitable for adults with conditions like atrial fibrillation (to prevent stroke) or those recovering from hip or knee replacement surgery (to prevent deep vein thrombosis and pulmonary embolism).


Contraindications and Cautions

Alkixa is not recommended for everyone, as it significantly increases the risk of bleeding. The medication is contraindicated and should not be used in individuals who have active pathological bleeding, a known severe hypersensitivity or allergic reaction to apixaban, or in patients with an artificial heart valve (prosthetic valve).

Consultation with a healthcare provider is essential, as use may require caution or may be contraindicated in patients with:

Condition Consideration
Bleeding Risks Bleeding problems, recent serious trauma, or a history of hemorrhagic stroke.
Organ Function Severe liver impairment or severe kidney disease.
Pregnancy/Nursing Generally not recommended for use during pregnancy or breastfeeding.

It is vital to inform your doctor about all other medications, including nonprescription and herbal products, as many drugs can interact with Alkixa and increase the risk of bleeding.

What should I know about interactions with other medicines?

Alkixa Interactions with other medicines and products

Alkixa (Alectinib) has a specific official interaction profile focusing on drug transporters and pharmacodynamic effects, as documented by regulatory authorities. No medicinal products are formally listed as contraindicated for co-administration in the product labeling.


Metabolic and Exposure Effects (Pharmacokinetics)

  • CYP3A Modulators: Co-administration with strong CYP3A inhibitors (e.g., posaconazole) or strong CYP3A inducers (e.g., rifampin) results in no clinically meaningful effect on the combined exposure of Alectinib and its active metabolite, M4.
  • Acid-Reducing Agents: Co-administration with acid-reducing agents (e.g., esomeprazole) also resulted in no clinically meaningful effect on the drug's exposure.
  • Transporter Substrates: Alectinib and M4 are documented as in vitro inhibitors of P-glycoprotein (P-gp) and BCRP. Co-administration with medicinal products that are substrates of P-gp or BCRP may result in increased plasma exposure of the co-administered drug.

Pharmacodynamic and Procedural Constraints

  • Heart Rate: Due to the potential for additive effects on heart rate, the official labeling advises evaluation of concomitant bradycardia-causing agents and anti-hypertensive medicines in cases where the patient experiences symptomatic bradycardia.
  • Timing: The regulatory label does not include mandatory time separation rules for doses. However, the drug must be administered with food as a requirement for consistent pharmacokinetic exposure.

Mechanism of Action

Targeting p21-Activated Kinase 1 (PAK1)

Alkixa functions as an inhibitor that primarily targets and disables the catalytic activity of the PAK1 enzyme. By binding to or near the active site, Alkixa structurally or allosterically blocks PAK1's ability to transfer a phosphate group to its substrate proteins. This direct molecular interaction disrupts a core signaling hub required for various cellular processes.


Modulating Proliferation and Survival Pathways

The inhibition of PAK1 activity initiates a cascade that suppresses signaling through pathways like MAPK and Rho GTPase axes. This mechanistic domain blocks the downstream signals that promote cellular proliferation, migration, and survival.


Limiting Cell Growth and Angiogenesis

By disrupting pro-survival signals and enabling pro-death signals (apoptosis), Alkixa alters the cellular life-death balance. This action results in the physiological consequence of suppressed cell growth and inhibition of angiogenesis (new blood vessel formation), thereby modulating tissue-level processes.

Dosage and Administration Information

How to Use Alkixa: Administration Guidelines

Alkixa (Alectinib) is administered based on precise, standardized protocols to ensure consistent dosing. The medicine is exclusively for oral use and is provided in 150 mg capsules.


Dosing and Schedule

The standard starting dose for adult patients across approved contexts is 600 mg, which is administered twice daily (BID), resulting in a total daily intake of 1200 mg. The medicine is taken with food to facilitate proper absorption. The capsules are swallowed whole and are not crushed, opened, or dissolved.


Duration of Treatment

The length of use is determined by the specific clinical setting:

  • Adjuvant Setting: Administration is continued for a fixed total duration of two years or until disease recurrence.
  • Metastatic Setting: Administration continues until there is evidence of disease progression or unacceptable toxicity.

Special Administration Rules

Specific protocols regarding dosage adjustments and timing errors are followed. For patients with severe hepatic impairment (Child-Pugh C), the starting dose is adjusted to 450 mg twice daily. If a scheduled dose is missed, or if vomiting occurs after a dose, extra doses are not taken and the next scheduled dose is taken at its designated time. This structured administration protocol governs the use of the drug.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Alkixa (Aldioxa)


Evidence for Oral Use: Gastric Mucosal Protection

Research exploring Alkixa's oral use examines its role as a compound studied for activity relevant to mucosal protection in the stomach lining. Studies have been conducted in both preclinical (animal) settings and older human clinical studies to investigate its influence on the gastric mucosa and on outcomes related to upper gastrointestinal issues. Findings from preclinical research often describe patterns observed in the studies where measurements of lesion size and integrity of the stomach lining were recorded following induced injury in animal models. However, the existing research base relies significantly on preclinical data and older clinical reports. Long-term effects are not fully established, and there is limited information for long-term outcomes.

Evidence for Topical Use: Tissue Healing and Epithelial Regeneration

The research for Alkixa's use in topical applications was explored in preclinical laboratory studies and animal models to explore its activity in settings relevant to skin and tissue processes. These studies examined wound dynamics, such as the rate of wound contraction and the overall time required for new skin to form. The research describes findings that describe patterns observed in animal models. The evidence base for topical use tends to focus heavily on the properties of one of the compound's components, and comparative evidence is lacking against contemporary standard treatments. Specific high-quality Randomized Controlled Trials (RCTs) assessing its use for complex wound types are not consistently available.


Evidence Gaps and Research Uncertainty

Evidence quality varies across studies, and the foundation of research is heavily supported by preclinical animal data and older clinical findings, meaning the relevance to contemporary care standards and other treatment options is sometimes uncertain. Sample sizes were modest in many of the older human studies. Studies help show what has been observed so far, but research does not determine whether an individual will respond similarly, and findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Alkixa (FAQ)

Q: How quickly should I expect to see the effects of Alkixa?

A: Studies and official information indicate that after taking a dose, the medicine reaches its highest blood concentration in approximately 4 to 6 hours. Consistent levels in the body, known as steady-state concentrations, are generally established within 7 days of beginning treatment.

Q: How long does Alkixa stay in your system?

A: Regulatory documents describe the elimination half-life of Alectinib, the active drug, as approximately 33 hours. The active breakdown product, M4, has an elimination half-life of about 31 hours. The half-life describes the time required for the amount of medicine in the body to be reduced by half.

Q: Is Alkixa considered a long-term or short-term treatment?

A: The official administration guidelines describe continuous treatment protocols, either for a fixed duration of two years (in the adjuvant setting) or continuously until evidence of disease progression or unacceptable side effects. This framing is consistent with a long-term treatment approach.

Q: Can I take Alkixa with my blood pressure medication?

A: The official drug information recommends evaluating the use of anti-hypertensive medicines if a patient develops symptomatic bradycardia (a slow heart rate). Bradycardia is a documented adverse reaction, and this information helps your healthcare provider assess the need for adjustments.

Q: Can Alkixa be used by older adults?

A: Safety data notes that older patients, defined as those aged 65 years and over, have been observed to report higher rates of certain common adverse effects. These effects include fatigue and peripheral edema (swelling).

Q: Are there different strengths of Alkixa available?

A: The medicine is supplied as 150 mg capsules. The specific dose prescribed to a patient is achieved by taking the required number of these 150 mg capsules. Regulatory information does not describe other strengths for the oral product.

Q: Is it normal to feel a little dizzy when first starting Alkixa?

A: Dizziness is listed in the official safety information as a possible symptom associated with a serious adverse reaction, particularly a slow heart rate (bradycardia). This finding emphasizes the importance of promptly reporting dizziness to your healthcare provider.

Q: Does Alkixa affect birth control pills?

A: Official guidance requires females of reproductive potential to use effective contraception methods during treatment and for a period of 5 weeks following the last dose. Similarly, male patients with female partners of reproductive potential are required to use effective contraception for 3 months after the last dose.

Q: What if I'm pregnant or trying to get pregnant and taking Alkixa?

A: Based on its established mechanism and findings from animal studies, official product information indicates that this medicine can cause harm to an unborn baby. For this reason, the medicine is generally not recommended during pregnancy, and official warnings inform patients of the potential risks.

Q: Can I take Alkixa if I have a history of heart issues?

A: Official safety information indicates the importance of informing your doctor of any existing or historical heart problems before starting the medicine. This is particularly relevant regarding conditions that involve a slow heart rate, known as bradycardia.

Q: What happens if Alkixa is taken with alcohol?

A: While some sources indicate no specific interaction, regulatory documents warn that because the medicine can cause liver damage (hepatotoxicity), alcohol consumption may increase the risk of liver problems. Additionally, alcohol may worsen some common side effects like nausea and fatigue.

Q: Does taking Alkixa interfere with driving or operating machinery?

A: Official regulatory information cautions against driving, operating machinery, or performing tasks requiring immediate alertness if a patient experiences vision problems or dizziness. This guidance is in place due to the risk of side effects that could impair these activities.

Q: When is the best time of day to take Alkixa?

A: The dosing protocol is twice daily (BID) and should be taken with food. To maintain consistent exposure, the doses should be taken at approximately the same times each day.

Q: Is it possible to be allergic to Alkixa?

A: Regulatory information indicates that patients should inform their healthcare team if they have any known allergies to the active ingredient or any other components of the capsule. This is a standard precaution taken before starting any medication.

Q: Can taking Alkixa cause weight gain or loss?

A: Weight increase is listed as a common adverse reaction in the clinical data for this medicine. Studies and official information indicate that weight gain was reported in up to 11% of patients.

Q: Why is Alkixa not recommended for people with [specific health condition]?

A: Regulatory documents specify a required starting dose reduction for people with severe hepatic impairment (Child-Pugh C). This adjustment is necessary due to documented increases in drug exposure in patients with liver function issues.

Q: Can Alkixa cause stomach upset or nausea?

A: Stomach issues are listed as common adverse effects reported in clinical studies. Specifically, nausea was reported in 14–18% of patients, and vomiting in 7–12% of patients in the data examined by regulatory authorities.

Q: Do I need special tests while I am taking Alkixa?

A: Regulatory guidelines require monitoring of certain laboratory parameters at specified intervals during the first months of treatment. These necessary tests include liver function tests (such as ALT, AST, and bilirubin) and Creatine Phosphokinase (CPK) levels.

Q: Is Alkixa available over the counter?

A: Official documents classify this medicine as a prescription product. It is intended for use under the supervision of a physician experienced in cancer treatment.

Q: Are there any specific lifestyle changes recommended while using Alkixa?

A: Official safety information notes the need to avoid unnecessary sun exposure while taking the medicine and for at least seven days after the last dose. Protective measures, such as using sunscreen (SPF 50 or greater) and wearing protective clothing, are recommended during this period.

Q: Is it true that Alkixa should not be taken with grapefruit?

A: Regulatory-based patient information generally advises against the consumption of grapefruit, starfruit, Seville oranges, pomegranate, or their respective juices while taking this medicine.

Q: What if I experience a rare side effect mentioned in the leaflet?

A: Official safety information consistently advises that patients should promptly contact their healthcare provider if they experience any new or worsening symptoms. This guidance applies especially to symptoms listed as serious adverse reactions, regardless of how rare they may be.

How should Alkixa be stored and disposed of?

How to Store and Dispose of Alkixa

The storage and disposal requirements for Alkixa (Alectinib capsules) are strictly defined in regulatory documents to ensure product stability and safety.

Storage Requirements

Alkixa must be stored at Controlled Room Temperature, specifically between 20 C and 25 C. To maintain stability, the capsules must be kept in their original container and the container must remain tightly closed to protect the medicine from moisture. The official labeling mandates that the container's desiccant must not be removed.

Child Safety and Disposal

For safety, the medication must be kept out of the sight and reach of children. Due to its classification as a cytotoxic medicinal product, unused or expired Alkixa must be treated as hazardous waste. Disposal must follow local requirements for cytotoxic medicinal products and the product must not be thrown away via wastewater or standard household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alkixa found in:

A-Z Index: